HUTCHMED H1 2026: China Oncology Rebounds, FRUZAQLA Goes Global, and ATTC Pipeline Advances
HCM is trading near its 52-week low of $9.77 (13% above the low).
Summary
HUTCHMED's H1 2026 results feature a sharp recovery in China oncology sales, rapid global expansion of FRUZAQLA, and progress across its ATTC pipeline, all supported by a $1.37B cash balance and reiterated full-year guidance.
Key Events · Earnings and Guidance · HCM
-
China Oncology Sales Rebound
Driven by ELUNATE in-market sales up 41% to $60.8M and SULANDA up 45% to $18.4M, total China oncology product sales reached $94.4M, a 32% increase over H1 2025.
-
FRUZAQLA Global Expansion
FRUZAQLA ex-US in-market sales grew roughly 70% to $68.9M, with the drug now approved or launched in 41 countries. Steady US sales contributed to total global in-market sales of $185.4M.
-
Profitability and Strong Cash Position
Net income attributable to HUTCHMED was $15.9M, and a cash balance of $1.37B provides ample resources to fund R&D and ATTC development.
-
Regulatory and Pipeline Milestones
The NMPA approved ELUNATE for 2L kidney cancer and ORPATHYS for 3L gastric cancer; sovleplenib NDAs were accepted for wAIHA and ITP with priority review; ATTC candidates HMPL-A251 and HMPL-A580 are in dose escalation, and HMPL-A830's IND was cleared.
Analysis · HCM · Life Sciences
A strong first half of 2026 saw China oncology product sales rebound over 40% and FRUZAQLA ex-US sales surge roughly 70%, underscoring HUTCHMED's commercial momentum. The company remained profitable with $15.9M in net income and a robust $1.37B cash position, which funds an accelerating ATTC pipeline. Multiple regulatory wins—including NMPA approvals for ELUNATE in kidney cancer and ORPATHYS in gastric cancer, plus NDA acceptances for sovleplenib in two indications—de-risk the late-stage portfolio. Reiterated full-year revenue guidance of $330M-$450M signals confidence in the commercial trajectory. This comprehensive update materially advances the investment thesis by demonstrating commercial execution, pipeline progress, and financial strength.
At the time of this filing, HCM was trading at $11.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $9.77 to $19.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.